Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Wisdom stevia GRAS notice

This article was originally published in The Tan Sheet

Executive Summary

FDA has no objections to Wisdom Natural Brands' affirmation that its stevia-based SweetLeaf Sweetener is generally recognized as safe, according to a letter the firm receives Sept. 1. Wisdom founder Jim May called FDA's validation "a tremendous victory" following research to prove the extract's safety and quality. Other firms including Blue California, Cargill and McNeil Nutritionals have received "no objection" notices from FDA regarding sweeteners made with the stevia preparation rebaudioside A (1"The Tan Sheet" July 6, 2009). SweetLeaf Sweetener was on the market for more than a year before Gilbert, Ariz.-based Wisdom received FDA's response to its GRAS affirmation

You may also be interested in...

People In Brief

Berg becomes GNC COO: General Nutrition Centers names David Berg the Pittsburgh firm's first chief operating officer, promoting him from executive VP, Global Business Development and COO for GNC's international operations. Berg, who will continue to directly report to GNC CEO Joe Fortunato, previously reached the posts of executive VP and COO in seven years with Best Buy International and for two years was president and COO of U.K.-based office equipment firm Danka Business Systems' international division, GNC said June 8

Supply's The Limit As Stevia-Based Sweeteners Gain In Popularity

Stevia-based sweetener marketers appear to have cleared the challenge of FDA acceptance, but face another in ensuring ready availability of South American stevia rebaudiana

Inovio Confirms Frontrunner Status In COVID-19 Vaccine Race, But Can It Prove Skeptics Wrong?

Its ‘virus chasing’ habits has given Inovio a bad reputation. But with backing from CEPI and Bill Gates, it has a chance to prove the doubters wrong.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts